NDA 209394 · Abbvie
Mavyret
Glecaprevir, Pibrentasvir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 3, 2017
Approved uses
8
Original approval plus efficacy supplements
Registered trials
58
30 Phase 3, 3 recruiting
FAERS reports
10,976
2,823 serious, 296 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions ( 5.1 )] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...
What it is approved for
From the label in effect Jun 25, 2025.
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14 )]. MAVYRET is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. ( 1 )
Mechanism: Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology ( 12.4 ) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 10, 2025 Supplement 19 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Jun 10, 2021 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Apr 10, 2020 Supplement 10 · Efficacy LabelLetter
- Sep 26, 2019 Supplement 7 · Efficacy LetterLabel
- Sep 26, 2019 Supplement 8 · Efficacy · priority review LetterLabelPediatric Other
- Apr 30, 2019 Supplement 6 · Efficacy · priority review OrphanLetterLabelPediatric CDTL Review
- Aug 6, 2018 Supplement 2 · Efficacy LabelLetter
- Aug 3, 2017 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- MAVYRET · GLECAPREVIR 100MG; PIBRENTASVIR 40MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glecaprevir" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 InfectionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02604017 · 703 participants · Start Oct 2015 · Primary completion Jan 2017
Drug: ABT-493/ABT-530 · For: Chronic Hepatitis C; Hepatitis C Virus; HCV
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02243293 · 694 participants · Start Sep 19, 2014 · Primary completion Oct 25, 2016
Drug: ABT-493; ABT-530 and 2 more · For: Chronic Hepatitis C; Hepatitis C Virus
AbbVieAbbVie (ABBV)
NCT03222583 · 546 participants · Start Oct 4, 2017 · Primary completion Oct 18, 2018
Drug: Placebo; Glecaprevir/Pibrentasvir · For: Hepatitis C Virus (HCV)
Sites: Beijing, China; Guangzhou, China; Changsha, China · 48 sites in all
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02640157 · 506 participants · Start Dec 2015 · Primary completion Oct 2016
Drug: ABT-493/ABT-530; Sofosbuvir and 1 more · For: Chronic Hepatitis C; Hepatitis C Virus; Genotype 3 Hepatitis C Virus
- A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530Pivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02441283 · 384 participants · Start Jun 22, 2015 · Primary completion Oct 15, 2019
Drug: ABT-493; ABT-530 · For: Hepatitis C
Sites: Dothan, Alabama; Bakersfield, California; Coronado, California · 42 sites in all
- Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C PatientsPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT03117569 · 380 participants · Start Aug 21, 2017 · Primary completion Dec 19, 2018
Drug: glecaprevir (300mg)/pibrentasvir (120mg) · For: Hepatitis C, Chronic
Sites: Boston, Massachusetts; New York, New York; Durham, North Carolina · 33 sites in all
- A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated CirrhosisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03089944 · 343 participants · Start Apr 28, 2017 · Primary completion Jul 31, 2019
Drug: Glecaprevir/Pibrentasvir · For: Hepatitis C Virus (HCV)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bakersfield, California · 113 sites in all
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02640482 · 304 participants · Start Nov 2015 · Primary completion Sep 2016
Drug: ABT-493/ABT-530; Placebo for ABT-493/ABT-530 · For: Chronic Hepatitis C Virus (HCV) Infection
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,568
- headache2,208
- nausea1,135
- pruritus662
- diarrhoea481
- vomiting317
- rash314
- dizziness232
- death231
- pain211
- insomnia201
- abdominal discomfort199
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 156 |
| 2018 | 3,515 |
| 2019 | 3,713 |
| 2020 | 1,203 |
| 2021 | 526 |
| 2022 | 715 |
| 2023 | 437 |
| 2024 | 282 |
| 2025 | 266 |
| 2026 | 163 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mavyret (Glecaprevir/Pibrentasvir)
2024 spending
$165M
Beneficiaries
6,721
12,457 claims
Per beneficiary
$24,598
$155.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $295,848,484 |
| 2021 | $259,730,649 |
| 2022 | $235,116,398 |
| 2023 | $232,993,526 |
| 2024 | $165,321,586 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co-formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults.
Kalluri HV, Oberoi RK, Chen Q, et al. · Clin Pharmacol Drug Dev 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C.
Llibre JM, Boesecke C, Moon J, et al. · J Hepatol 2026 · Clinical Trial, Phase III, Multicenter Study
- Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder.
Watts BV, Hoyt JE, Disano KD, et al. · Psychopharmacol Bull 2026 · Clinical Trial
- Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
Wyles D, Weiland O, Yao B, et al. · J Hepatol 2019 · Clinical Trial, Phase III, Letter
- Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta-Analysis.
Le DHH, Nguyen DC, Kanokudom S, et al. · Rev Med Virol 2025 · Comparative Study, Meta-Analysis
- Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.
Madsen LW, Christensen PB, Hansen JF, et al. · Viruses 2022 · Multicenter Study, Randomized Controlled Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.